Weight gain during pregnancy in women with HIV receiving different antiretroviral regimens.
Journal
Antiviral therapy
ISSN: 2040-2058
Titre abrégé: Antivir Ther
Pays: England
ID NLM: 9815705
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
16
12
2020
pubmed:
19
1
2021
medline:
26
10
2021
entrez:
18
1
2021
Statut:
ppublish
Résumé
No published studies have evaluated in pregnant women with HIV weight gain with different antiretroviral drug classes. Data from a national cohort study were used. We compared absolute weight gain and occurrence of excessive weight gain in women with HIV who received during pregnancy integrase inhibitors (INSTI), protease inhibitors (PI), or non-nucleoside reverse transcriptase inhibitors (NNRTI). Excessive weight gain was defined according to the Institute of Medicine recommendations. Possible predictors of weight gain were assessed using univariate and multivariate analyses. Among 273 cases (PI: 191, NNRTI: 43, INSTI: 39), the mean weight increase was 11.3 kg, and 25.4% of the mothers had an excessive weight increase. No significant differences were found among the three treatment groups for absolute weight increase, occurrence of excessive weight gain, infant birthweight, and other pregnancy and laboratory outcomes. The comparisons of individual drugs, although based on a limited number of cases, suggested no major differences. A significant positive correlation was found between weight gain and CD4 No significant differences in absolute weight change or occurrence of excessive weight gain were found among women with HIV who received during pregnancy different classes of antiretroviral drugs.
Sections du résumé
BACKGROUND
No published studies have evaluated in pregnant women with HIV weight gain with different antiretroviral drug classes.
METHODS
Data from a national cohort study were used. We compared absolute weight gain and occurrence of excessive weight gain in women with HIV who received during pregnancy integrase inhibitors (INSTI), protease inhibitors (PI), or non-nucleoside reverse transcriptase inhibitors (NNRTI). Excessive weight gain was defined according to the Institute of Medicine recommendations. Possible predictors of weight gain were assessed using univariate and multivariate analyses.
RESULTS
Among 273 cases (PI: 191, NNRTI: 43, INSTI: 39), the mean weight increase was 11.3 kg, and 25.4% of the mothers had an excessive weight increase. No significant differences were found among the three treatment groups for absolute weight increase, occurrence of excessive weight gain, infant birthweight, and other pregnancy and laboratory outcomes. The comparisons of individual drugs, although based on a limited number of cases, suggested no major differences. A significant positive correlation was found between weight gain and CD4
CONCLUSIONS
No significant differences in absolute weight change or occurrence of excessive weight gain were found among women with HIV who received during pregnancy different classes of antiretroviral drugs.
Substances chimiques
Anti-HIV Agents
0
Reverse Transcriptase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM